VYNE Therapeutics
(NASDAQ) VYNE
VYNE Therapeutics Financials at a Glance
Market Cap
$20.03M
Revenue (TTM)
$570.00K
Net Income (TTM)
$26.48M
EPS (TTM)
$-0.65
P/E Ratio
-0.92
Dividend
$0.00
Beta (Volatility)
1.03 (Average)
Dividend
$0.00
Beta (Volatility)
1.03 (Average)
Price
$0.61
Volume
125,712.441
Open
$0.61
Price
$0.61
Volume
125,712.441
Open
$0.61
Previous Close
$0.60
Daily Range
$0.59 - $0.61
52-Week Range
$0.28 - $1.99
Dividend
$0.00
Beta (Volatility)
1.03 (Average)
Price
$0.61
Volume
125,712.441
Open
$0.61
Previous Close
$0.60
Daily Range
$0.59 - $0.61
52-Week Range
$0.28 - $1.99
VYNE News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout VYNE Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
10
CEO
David Domzalski
Website
www.vynetherapeutics.comHeadquarters
Bridgewater, NJ 08807, US
VYNE Financials
Key Financial Metrics (TTM)
Gross Margin
99%
Operating Margin
-52%
Net Income Margin
-46%
Return on Equity
-67%
Return on Capital
-1%
Return on Assets
-88%
Earnings Yield
-1.09%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$20.03M
Shares Outstanding
33.32M
Volume
125.71K
Short Interest
0.00%
Avg. Volume
346.15K
Financials (TTM)
Gross Profit
$547.00K
Operating Income
$29.75M
EBITDA
$26.73M
Operating Cash Flow
$33.12M
Capital Expenditure
$0.00
Free Cash Flow
$33.12M
Cash & ST Invst.
$29.01M
Total Debt
$0.00
VYNE Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$130.00K
+54.8%
Gross Profit
$125.00K
+48.8%
Gross Margin
96.15%
N/A
Market Cap
$20.03M
N/A
Market Cap/Employee
$1.54M
N/A
Employees
13
N/A
Net Income
$4.84M
+59.8%
EBITDA
$5.21M
+59.2%
Quarterly Fundamentals
Net Cash
$29.01M
-52.8%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
-100.0%
Return on Assets
-87.81%
N/A
Return on Invested Capital
-1.07%
N/A
Free Cash Flow
$3.76M
+58.7%
Operating Cash Flow
$3.76M
+58.2%